Trials / Completed
CompletedNCT04906941
Assessment of the Impact of Gadolinium Injection on the Measurement of the QSM Signal
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 73 (actual)
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild · Network
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Patients meeting the inclusion and non-inclusion criteria will be offered to participate in the study. If they agree, they will perform an MRI without injection to obtain the QSM then perform the MRI with injection that was prescribed to them as part of the care, then they will perform a second time the MRI without injection to obtain the QSM. They will also answer a short questionnaire documenting their previous exposure to gadolinium.
Detailed description
Patients meeting the inclusion and non-inclusion criteria will be offered to participate in the study. If they agree, they will perform an MRI without injection to obtain the QSM then perform the MRI with injection that was prescribed to them as part of the care, then they will perform a second time the MRI without injection to obtain the QSM. They will also answer a short questionnaire documenting their previous exposure to gadolinium.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | MRI | SWI QSM 1.0iso 8 echos sequence performed before and after the injected MRI prescribed as part of the treatment. \* Sense 2 \* 2: 9min33s |
Timeline
- Start date
- 2022-01-21
- Primary completion
- 2023-07-19
- Completion
- 2023-07-19
- First posted
- 2021-05-28
- Last updated
- 2026-01-05
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT04906941. Inclusion in this directory is not an endorsement.